Findings

What do systematic reviews say?

4 questions · 8 findings · 1 reviews · Neonatal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 75%GRADE not reported 0 · 0%Very low 2 · 25%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

High‐dose vs standard‐dose strategies

Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants at risk for apnea

It is very uncertain whether high‐dose changes major neurodevelopmental disability in children aged 3 to 5 years CA compared with standard‐dose strategies (very low certainty).

1 finding from 1 review

Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
RR 0.79 [0.51, 1.24]
1 study · 46 participants
Very low

High‐dose vs standard‐dose strategies

Major neurodevelopmental disability in children aged 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

The review found no eligible studies for this question.

3 findings from 1 review

Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
RR 0.79
1 study · 46 participants
Very low

High‐dose vs standard‐dose strategies

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants at risk for apnea

The review found no eligible studies for this question.

1 finding from 1 review

Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose vs standard‐dose strategies

Mortality or major neurodevelopmental disability in children aged 18 to 24 months and 3 to 5 years CA · preterm infants with or at risk for apnea of prematurity

The review found no eligible studies for this question.

3 findings from 1 review

Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found